Endo International plc (NASDAQ: ENDP), a generics and specialty branded pharmaceutical company, announced yesterday its financial results for the second-quarter of 2019.

The company reported revenue of USD700m in the second-quarter of 2019, down 2% compared to the year-ago period.

The firm posted net loss from continuing operations of USD98m in the second quarter of 2019 compared to a net loss from continuing operations of USD52m in the year-ago period.

Paul Campanelli, president and chief executive officer of Endo, said, 'I am pleased with our second-quarter 2019 operating performance, led by continued year-over-year double-digit percentage growth in revenues of our Sterile Injectables segment and in the Specialty Products portfolio of our Branded Pharmaceuticals segment. XIAFLEX grew 18% in the quarter, reflecting continued demand growth as a result of successful commercial execution and promotional investment. We are on target to meet our previously provided full-year financial guidance and remain highly focused on the continued execution of our multiyear turnaround plan in a challenging external environment.'